01—Abstract
Summary
Summary of the 10-Q filed October 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. reported strong financial results for the nine months ended September 30, 2025, with total revenues of $10.46 billiona, a slight increase from the same period in 2024.
Net income also saw a positive trend, reaching $3.66 billionb, up from $3.49 billion in the prior year. Diluted earnings per share were $33.61, an increase from $30.23. The company's product sales, while experiencing a decline in EYLEA revenue due to increased competition and the transition to EYLEA HD, were bolstered by significant growth in Dupixent and Libtayo sales.
Collaboration revenue, primarily from Sanofi, also showed robust growth, driven by strong Dupixent performance. Operating expenses increased due to higher R&D investments, particularly in direct R&D for key programs, though SG&A expenses decreased. The company continued its share repurchase program and declared regular quarterly dividends, underscoring a commitment to returning capital to shareholders.
02—Key points
Key Highlights
- Total revenues for the first nine months of 2025 increased slightly to $10.46 billion from $10.41 billion in the comparable period of 2024.
- Net income rose to $3.66 billion for the nine months ended September 30, 2025, compared to $3.49 billion in the same period of 2024.
- Diluted earnings per share improved to $33.61 from $30.23 year-over-year.
- Net product sales saw a decline, primarily driven by EYLEA sales impacted by competition and the transition to EYLEA HD, though EYLEA HD sales grew.
- Collaboration revenue, largely from Sanofi, increased significantly due to strong Dupixent performance, reaching $4.24 billion for the nine months ended September 30, 2025.
- Research and development expenses increased by approximately 13.6% to $4.22 billion for the nine months ended September 30, 2025, reflecting continued investment in pipeline advancement.
- The company repurchased approximately $2.79 billion of its common stock during the first nine months of 2025.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 28, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $3.75B$3.72B | +0.9% |
| R&D Expenses | $1.48B$1.27B | +16.0% |
| SG&A Expenses | $657.80M$714.40M | −7.9% |
| Operating Expenses | $2.73B$2.54B | +7.3% |
| Operating Income | $1.03B$1.18B | −12.9% |
| Net Income | $1.46B$1.34B | +8.9% |
| EPS (Basic) | $14.09$12.40 | +13.6% |
| EPS (Diluted) | $13.62$11.54 | +18.0% |
| Shares Outstanding (Basic) | 103.60M108.10M | −4.2% |
| Shares Outstanding (Diluted) | 107.20M116.20M | −7.7% |
05—Questions
Frequently Asked Questions
How did Regeneron's revenue and net income perform in the first nine months of 2025?
Regeneron reported total revenues of $10.46 billion for the nine months ended September 30, 2025, a slight increase from $10.41 billion in the same period of 2024. Net income increased to $3.66 billion from $3.49 billion in the prior year, with diluted earnings per share rising to $33.61 from $30.23.
What is the impact of competition on EYLEA sales?
EYLEA sales have been negatively impacted by increased competition from other anti-VEGF products, including biosimilars and compounded bevacizumab. The transition of patients to EYLEA HD also contributed to the decline in EYLEA sales. The company expects continued competitive pressure and potential further declines in EYLEA sales.
How is the collaboration with Sanofi contributing to revenue?
The collaboration with Sanofi, primarily driven by Dupixent sales, is a significant revenue driver. For the nine months ended September 30, 2025, collaboration revenue from Sanofi increased to $4.24 billion, reflecting strong performance and increased profits from Dupixent and Kevzara.
What is the company's approach to capital allocation?
Regeneron continues to actively repurchase its common stock, with $2.156 billion remaining available under its share repurchase programs as of September 30, 2025. Additionally, the company declared quarterly cash dividends of $0.88 per share, demonstrating a commitment to returning capital to shareholders.
06—Continue